319 related articles for article (PubMed ID: 26780934)
1. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.
Samulin Erdem J; Skaug V; Bakke P; Gulsvik A; Haugen A; Zienolddiny S
BMC Cancer; 2016 Jan; 16():28. PubMed ID: 26780934
[TBL] [Abstract][Full Text] [Related]
2. Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis.
Li Q; Liu F; Zhang Y; Fu L; Wang C; Chen X; Guan S; Meng X
Oncotarget; 2016 Jun; 7(23):34520-31. PubMed ID: 27150062
[TBL] [Abstract][Full Text] [Related]
3. SOX2 mediates cisplatin resistance in small-cell lung cancer with downregulated expression of hsa-miR-340-5p.
Cui F; Hao ZX; Li J; Zhang YL; Li XK; He JX
Mol Genet Genomic Med; 2020 May; 8(5):e1195. PubMed ID: 32130794
[TBL] [Abstract][Full Text] [Related]
4. The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR-155-Rb1 pathway.
Liu M; Zhou K; Huang Y; Cao Y
J Exp Clin Cancer Res; 2015 Oct; 34():121. PubMed ID: 26467212
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of miR-638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC.
Xia Y; Wu Y; Liu B; Wang P; Chen Y
FEBS Lett; 2014 Jun; 588(14):2238-45. PubMed ID: 24842609
[TBL] [Abstract][Full Text] [Related]
6. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-383 is a tumor suppressor and potential prognostic biomarker in human non-small cell lung caner.
Shang Y; Zang A; Li J; Jia Y; Li X; Zhang L; Huo R; Yang J; Feng J; Ge K; Yang Y; Zhang Y; Jiang J
Biomed Pharmacother; 2016 Oct; 83():1175-1181. PubMed ID: 27551765
[TBL] [Abstract][Full Text] [Related]
8. Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features.
Capodanno A; Boldrini L; Proietti A; Alì G; Pelliccioni S; Niccoli C; D'Incecco A; Cappuzzo F; Chella A; Lucchi M; Mussi A; Fontanini G
Int J Oncol; 2013 Sep; 43(3):765-74. PubMed ID: 23820752
[TBL] [Abstract][Full Text] [Related]
9. By downregulating Ku80, hsa-miR-526b suppresses non-small cell lung cancer.
Zhang ZY; Fu SL; Xu SQ; Zhou X; Liu XS; Xu YJ; Zhao JP; Wei S
Oncotarget; 2015 Jan; 6(3):1462-77. PubMed ID: 25596743
[TBL] [Abstract][Full Text] [Related]
10. Putative stemness markers octamer-binding transcription factor 4, sex-determining region Y-box 2, and NANOG in non-small cell lung carcinoma: A clinicopathological association.
Upadhyay VA; Shah KA; Makwana DP; Raval AP; Shah FD; Rawal RM
J Cancer Res Ther; 2020; 16(4):804-810. PubMed ID: 32930122
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC).
Zhang JG; Wang JJ; Zhao F; Liu Q; Jiang K; Yang GH
Clin Chim Acta; 2010 Jun; 411(11-12):846-52. PubMed ID: 20223231
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
14. The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.
Lee SY; Jeon HS; Hwangbo Y; Jeong JY; Park JY; Lee EJ; Jin G; Shin KM; Yoo SS; Lee J; Lee EB; Cha SI; Kim CH; Park JY
Mol Carcinog; 2015 Feb; 54(2):93-101. PubMed ID: 24038464
[TBL] [Abstract][Full Text] [Related]
15. Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
Bjaanæs MM; Nilsen G; Halvorsen AR; Russnes HG; Solberg S; Jørgensen L; Brustugun OT; Lingjærde OC; Helland Å
BMC Cancer; 2021 Oct; 21(1):1089. PubMed ID: 34625038
[TBL] [Abstract][Full Text] [Related]
16. Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data.
Xu S; Wang Y; Ren F; Li X; Ren D; Dong M; Chen G; Song Z; Chen J
Cancer Med; 2020 Oct; 9(20):7686-7694. PubMed ID: 32857918
[TBL] [Abstract][Full Text] [Related]
17. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.
Díaz-García CV; Agudo-López A; Pérez C; López-Martín JA; Rodríguez-Peralto JL; de Castro J; Cortijo A; Martínez-Villanueva M; Iglesias L; García-Carbonero R; Fresno Vara JA; Gámez-Pozo A; Palacios J; Cortés-Funes H; Paz-Ares L; Agulló-Ortuño MT
Carcinogenesis; 2013 May; 34(5):1031-8. PubMed ID: 23349018
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14).
Wang R; Wang ZX; Yang JS; Pan X; De W; Chen LB
Oncogene; 2011 Jun; 30(23):2644-58. PubMed ID: 21358675
[TBL] [Abstract][Full Text] [Related]
19. Expression of miR-150 and miR-3940-5p is reduced in non-small cell lung carcinoma and correlates with clinicopathological features.
Sun Y; Su B; Zhang P; Xie H; Zheng H; Xu Y; Du Q; Zeng H; Zhou X; Chen C; Gao W
Oncol Rep; 2013 Feb; 29(2):704-12. PubMed ID: 23228962
[TBL] [Abstract][Full Text] [Related]
20. Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants.
Deben C; Van den Bossche J; Van Der Steen N; Lardon F; Wouters A; de Beeck KO; Hermans C; Jacobs J; Peeters M; Van Camp G; Rolfo C; Deschoolmeester V; Pauwels P
Tumour Biol; 2017 Feb; 39(2):1010428317694327. PubMed ID: 28240049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
